2021 - IHE

Norlin JM, Kellerborg L, Odin P Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson’s Disease: A Swedish Register-Based Study in 1823 Observations Pharmacoeconomics, 2021 Oct;39(10):1141-1149
DOI: 10.1007/s40273-021-01056-z
Arthursson V, Rosén R, Norlin JM, Gralén K, Toth E, Syk I, Thorlacius H, Rönnow CF Cost Comparisons Of Endoscopic And Surgical Resection Of T1 Rectal Cancer Endoscopy 2021; 53(S 01): S253-S254
DOI: 10.1055/s-0041-1724964
Hofmarcher T, Keel G, Lindgren P Cancer care and access to cancer drugs in Asia-Pacific – Main report IHE Report 2021:3, IHE: Lund, Sweden
Hofmarcher T, Keel G, Lindgren P Pricing policies for off-patent drugs in Asia-Pacific IHE Report 2021:3g, IHE: Lund, Sweden
Hofmarcher T, Keel G, Lindgren P Health spending on cancer drugs and unmet patient needs in Asia-Pacific IHE Report 2021:3f, IHE: Lund, Sweden
Hofmarcher T, Keel G, Lindgren P Patient access to innovative cancer drugs in Asia-Pacific IHE Report 2021:3e, IHE: Lund, Sweden
Olsson P, Skröder C, Ahlbeck L, Hjalte F, Welin K-O, Westin U, Andersson M, Ahlström-Emanuelsson C, Cardell L-O HealthSWEDE: costs with sublingual immunotherapy—a Swedish questionnaire study Allergy, Asthma & Clinical Immunology 17, 55 (2021)
DOI: https://doi.org/10.1186/s13223-021-00560-3
Hofmarcher T, Keel G, Lindgren P Health spending on cancer in Asia-Pacific IHE Report 2021:3d, IHE: Lund, Sweden
Hofmarcher T, Keel G, Lindgren P The burden of cancer in Asia-Pacific IHE Report 2021:3c, IHE: Lund, Sweden
Hofmarcher T, Keel G, Lindgren P Cancer care and access to cancer drugs in Asia-Pacific – Executive summary IHE Report 2021:3b, IHE: Lund, Sweden

Back »Next »